An Open Label, Long Term Safety Trial of BI 655130 Treatment in Patients With Moderate to Severely Active Ulcerative Colitis Who Have Completed Previous BI 655130 Trials
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2019
Price : $35 *
At a glance
- Drugs Spesolimab (Primary) ; Spesolimab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 19 Aug 2019 Planned End Date changed from 30 Mar 2030 to 30 Mar 2031.
- 19 Aug 2019 Planned primary completion date changed from 30 Mar 2030 to 30 Mar 2031.
- 13 Nov 2018 Status changed from not yet recruiting to recruiting.